Therapeutic Variables in Cataract Surgery

This study has been completed.
Sponsor:
Information provided by:
Innovative Medical
ClinicalTrials.gov Identifier:
NCT00407017
First received: November 30, 2006
Last updated: August 17, 2007
Last verified: August 2007
  Purpose

The purpose of this study is to compare patient outcomes in following cataract surgery in patients randomized to one of two surgical kits.


Condition Intervention Phase
Cataract Surgery
Drug: Gatifloxacin
Drug: Ketorolac LS
Drug: Pred Forte
Drug: Moxifloxacin
Drug: Nepafenac
Drug: EconoPred Plus
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind

Resource links provided by NLM:


Further study details as provided by Innovative Medical:

  Eligibility

Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Males or females scheduled to undergo cataract surgery
  • Patients can be receiving monofocal IOLs only
  • Likely to complete all study visits and able to provide informed consent
  • Visual potential of 20/25 or better

Exclusion Criteria:

  • Known contraindications to any study medication or ingredients
  • Active ocular diseases or uncontrolled systemic disease
  • Active ocular allergies
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00407017

Locations
United States, Florida
The Center for Excellence in Eye Care
Miami, Florida, United States, 33176
Sponsors and Collaborators
Innovative Medical
Investigators
Principal Investigator: William Trattler, MD The Center For Excellence in Eye Care
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00407017     History of Changes
Other Study ID Numbers: 5264-T
Study First Received: November 30, 2006
Last Updated: August 17, 2007
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Cataract
Lens Diseases
Eye Diseases
Methylprednisolone acetate
Prednisolone acetate
Methylprednisolone
Methylprednisolone Hemisuccinate
Prednisolone
Ketorolac
Prednisolone hemisuccinate
Prednisolone phosphate
Gatifloxacin
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Agents
Gastrointestinal Agents
Neuroprotective Agents
Protective Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents

ClinicalTrials.gov processed this record on April 23, 2014